SCHEMBL147991

SCHEMBL147991

COc1cccc(-c2cccc3c2[nH]c2ccccc23)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP14 Q460N5 4/20 0.57
NR1I2 O75469 1/20 0.54
CYP1A2 P05177 1/20 0.54
VDR P11473 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2B6 P20813 1/20 0.54
AHR P35869 1/20 0.54
NR1I3 Q14994 1/20 0.54
ALDH1A1 P00352 2/20 0.54
KDM4E B2RXH2 1/20 0.54
MEN1 O00255 1/20 0.54
MAPT P10636 1/20 0.54
HPGD P15428 1/20 0.54
KMT2A Q03164 1/20 0.54
HSD17B10 Q99714 1/20 0.54
CHRM4 P08173 1/20 0.50
DRD2 P14416 1/20 0.50
HTR7 P34969 1/20 0.50
TUBB4A P04350 1/20 0.49
TUBB P07437 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29152741 0.90 PARP14 (0.52) PARP14NR1I2CYP1A2VDRCYP2C9
SCHEMBL27940400 0.85 PARP14 (0.58) PARP14ALDH1A1KDM4EMEN1MAPT
SCHEMBL30307455 0.85 PARP14 (0.49) PARP14NR1I2CYP1A2VDRCYP2C9
SCHEMBL187300 0.84 KIF11 (0.53) PARP14AHRALDH1A1HSD17B10BCHE
SCHEMBL29394785 0.84 KIF11 (0.53) PARP14AHRALDH1A1HSD17B10BCHE
SCHEMBL12180919 0.84 KDM4E (0.56) PARP14NR1I2CYP1A2VDRCYP2C9
SCHEMBL5488306 0.83 PARP14 (0.53) PARP14NR1I2CYP1A2VDRCYP2C9
SCHEMBL867558 0.82 KIF11 (0.52) PARP14ALDH1A1HSD17B10BCHEKIF11
SCHEMBL30950767 0.82 KIF11 (0.52) PARP14ALDH1A1HSD17B10BCHEKIF11
SCHEMBL411756 0.82 PARP14 (0.54) PARP14NR1I2CYP1A2VDRCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 PARP14 649/4885NR1I2 1361/4885CYP1A2 2286/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 PARP14 649/4885NR1I2 1361/4885CYP1A2 2286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.